The article reviews metabolomics-driven approaches for identifying therapeutic targets in drug discovery, highlighting the challenges and limitations of current methods. Emerging technologies like single-cell metabolomics, artificial intelligence, and mass spectrometry imaging are explored to enhance target discovery.
Researchers have identified a 177-gene signature common to metastasis across cancers, allowing for personalized risk assessment and potential therapies. The discovery could lead to broader treatment options, faster drug access, and improved patient outcomes.
Positive Phase 1 trial results suggest ISM5411's gut-restrictive property and favorable pharmacokinetic profile, validating its potential for treating inflammatory bowel disease. Insilico Medicine expects to initiate a Phase 2 proof-of-concept study in active ulcerative colitis patients.
A University of Oklahoma research team has developed a breakthrough method of adding a single nitrogen atom to bioactive molecules, transforming them into new pharmacophores. This process, called skeletal editing, could open up uncharted regions of chemical space in drug discovery, making existing drugs cheaper and more accessible.
Researchers at MD Anderson Cancer Center have made significant breakthroughs in smoking cessation treatments, with a study finding that varenicline plus counseling is the most effective treatment for individuals with major depressive disorder. Additionally, a new radiotherapy technique demonstrates effectiveness in treating metastatic ...
The study uses generative AI to identify and optimize potent and selective HPK1 inhibitors for immunotherapy. The results show a relatively balanced candidate compound with adequate in vitro ADME, in vivo PK properties, good oral bioavailability, and robust in vivo efficacy in various cancer models.
A team of researchers at USC will receive funding to test a novel approach to slowing age-related cognitive decline, targeting the brain's lymphatic system. The grant aims to delay the onset of Alzheimer's and Parkinson's disease by clearing waste buildup.
Insilico Medicine has received its first clinical milestone payment of $10 million from Exelixis for XL309, a selective USP1 inhibitor discovered with the company's AI platform. The drug is being developed for advanced solid tumors and has shown efficacy in preclinical studies.
SPACe enables researchers to analyze large datasets in an efficient way, capturing the full diversity of cellular responses. The platform provides a more nuanced understanding of how drugs interact with cells, revealing insights into mechanisms beyond cell death.
Insilico Medicine has nominated ISM8969, an orally available NLRP3 inhibitor, as a potential treatment for various inflammatory diseases. The compound has shown promising results in preclinical evaluation studies, including balanced druggability and efficacy against inflammation.
Insilico Medicine has successfully integrated cutting-edge generative AI models into its platform, achieving significant increases in accuracy and speed. The company's AI-powered solutions have shown promising results in preclinical candidates and Phase II clinical trials.
Insilico Medicine has developed an innovative platform using generative AI to discover novel molecules. The company has nominated over 20 preclinical candidates and received IND clearance for 10 molecules.
The new effort aims to rapidly transform academic breakthroughs into life-saving therapies for a range of medical conditions. Autobahn Labs will invest up to $5 million per selected project to support the development of new pharmaceuticals.
Insilico Medicine has received FDA clearance for ISM5939, a potential best-in-class oral small molecule inhibitor targeting ENPP1 for the treatment of solid tumors. ISM5939 demonstrated robust anti-tumor efficacy in preclinical studies and showed favorable safety profiles.
Researchers found neurotransmitters GABA and choline in the venom of estuarine and reef stonefish, which can modulate cardiovascular function. The discovery could aid in targeted treatments and venom-derived compound development for drug discovery.
Researchers at New York University developed a mathematical approach, Crystal Math, to predict molecular crystal structures in hours, bypassing weeks or months of supercomputer processing. This breakthrough could speed up R&D for drugs and electronic devices.
Argonne is using AI, high performance computing, simulation and structural biology to research novel ways to fight cancer and transform vaccine discovery. The lab aims to compress the drug discovery timeline and develop toolkits for broadly effective vaccines against multiple viral threats.
The Phase IIa trial of ISM001-055 showed dose-dependent improvement in forced vital capacity (FVC) and percent predicted FVC, suggesting potential to slow or reverse disease progression. The treatment also demonstrated a favorable pharmacokinetics profile with minimal adverse events.
Insilico Medicine has entered into a revolving loan facility of up to US$100 million with HSBC, enabling the company's global expansion and AI-driven innovation in biotechnology. The credit line will support Insilico's proprietary novel drug discovery pipeline and its end-to-end diversified AI platform, Pharma.AI.
The new portal connects genetic variant data with protein sequence and structural information, enabling easy visualization of variants on protein 3D structures. This facilitates the analysis of genetic variants' impact on protein function and structure.
Dr. Wai Hong Lo, PhD, has been appointed as the new Editor-in-Chief of ASSAY and Drug Development Technologies, succeeding Dr. Bruce Melancon. Dr. Lo aims to enhance online accessibility, incorporate visuals, and increase social media engagement to reach a broader audience.
Scientists have identified a key driver of brain inflammation in neurological diseases, proposing a new treatment approach by neutralizing fibrin. This protein, involved in blood coagulation, triggers neurologic diseases by hijacking the immune system, resulting in damaged neurons.
Researchers are creating microphysiological systems to simulate infection and treatment in vitro, linking human lung and brain tissue models. This project aims to explore the relationship between respiratory diseases and neurological symptoms, potentially leading to new treatments.
Researchers found that the oral medication palbociclib stabilized tumor growth and reduced blood tumor marker levels in patients with peritoneal mucinous carcinomatosis, a form of appendix cancer often resistant to standard chemotherapy. The study's findings introduce a first targeted therapy for this rare disease.
Researchers at KAIST successfully developed single-atom editing technology that maximizes drug efficacy by converting oxygen atoms into nitrogen atoms in furan compounds. This breakthrough technology enables selective editing of complex natural products or pharmaceuticals, opening new doors for building libraries of drug candidates.
Researchers have developed a cell culture platform to form two distinct, interconnected vascular networks, replicating human physiology and reducing animal testing costs. This breakthrough enables the study of cellular interactions in vascularized tissues.
Researchers at IOCB Prague successfully isolated the proteasome enzyme complex of the T. vaginalis parasite, enabling them to develop new medicines that can target this parasite without harming humans. This breakthrough has critical implications for treating trichomoniasis and reducing HIV risk.
Scientists at The Wistar Institute have identified a novel series of SARS-CoV-2 Mpro inhibitors that effectively inhibit viral replication in vitro against multiple COVID variants. These compounds also synergize with existing antivirals, offering promise for developing future therapies.
Recent research highlights microwave-induced synthesis as a transformative potential in drug discovery and development. This efficient technique enables rapid preparation of diverse N-heterocycles, including biologically active molecules such as pyrimidines, thiazoles, and quinolines.
Researchers created SmartCADD, an AI-powered virtual tool combining quantum mechanics and Computer Assisted Drug Design techniques. The tool speeds up the screening of chemical compounds, significantly reducing drug discovery timelines and identifying promising HIV drug candidates.
Removing protected class regulation from Medicare Part D policies could reduce US prescription drug spending, potentially saving $47 billion between 2011-2019. The study found that rebates for protected classes of drugs grew at a slower pace than non-protected classes.
A study from Goethe University Frankfurt reveals that venomous crustaceans, specifically remipede crabs in Mexican cenote caves, contain a variety of toxins with pharmacological potential. The xibalbines peptides effectively inhibit potassium channels and activate signaling pathways involved in pain sensitization.
Researchers at the University of Copenhagen's Quantum for Life Centre have developed a new mathematical recipe to make quantum simulators more scalable and efficient. This breakthrough could speed up the development of new medicines from years to months by predicting how molecules behave in the human body before laboratory trials.
KiNet is an interactive web portal that enables researchers to visualize and study kinase-substrate interactions in systemwide contexts. This facilitates the understanding of kinase functions and their implications in diseases such as cancer, neurodegenerative disorders, and cardiovascular diseases.
Researchers at UConn have discovered a novel miRNA-141-3p inhibitor that successfully reduces stroke damage and extinguishes inflammatory fires in the brain. The treatment has shown swift restoration of motor function and memory in mouse models, offering new hope for patients affected by strokes.
Researchers at the University of Virginia Health System have identified a crucial biological switch that regulates renin production in certain cells, allowing them to control blood pressure. This discovery provides important direction for future research into high blood pressure and cardiovascular disease treatment.
The European capacity for antibiotic research and development requires sustained investment to combat growing resistance. Collaboration and risk-sharing can help keep companies in anti-infective drug development, as a temporary funding strategy may lead to lost efforts.
Researchers developed a label-free biological sensing method that can detect substances at the zeptomolar level, significantly improving drug testing and research capabilities. This advancement has the potential to lead to portable sensors for environmental toxins, food quality monitoring, and cancer screening.
Researchers at UCSF develop a method to target GTPases, enzymes involved in Parkinson's and many other diseases, by using drugs targeting the K-Ras oncogene. This approach reveals new drug binding sites that could not be predicted by computational tools.
Researchers investigated peptide clumping behavior using molecular dynamics simulations and AI techniques. They discovered that aromatic amino acids enhance aggregation, while hydrophilic ones inhibit it, offering insights into peptide structure and function.
Researchers have developed a new method to increase speed and success rates in drug discovery by combining data from the Library of Integrated Network-based Cellular Signatures with targeted docking simulations. This approach can accelerate the drug research process, identifying potentially effective compounds more efficiently.
A University of Oklahoma researcher has been awarded a NIH grant to evaluate thousands of natural products with therapeutic potential. The goal is to identify specific components of these products that have anticancer properties and understand how they work.
Researchers successfully put tadpoles into a hibernation-like state using FDA-approved donepezil (DNP), which could be repurposed to save millions of lives every year. The drug induces torpor-like symptoms and can be easily administered, making it a promising tool for emergency situations.
Researchers at Purdue University have received an additional $95,000 from the Trask Innovation Fund to further de-risk their technology for patent-pending drought-resistant soybean plants. Herman Sintim's team aims to develop novel compounds that potentially inhibit TAK1, a protein kinase shown to play key roles in arthritis.
Using Explainable AI (XAI), researchers analyzed AI model predictions for antibiotic candidates, identifying critical molecular structures and variables. This helped improve predictive models, which can now be trained on what's truly important for activity.
A wearable sensor supported by machine learning models can continuously monitor and quantify FOG episodes, providing an accurate picture of a patient's condition. This technology has the potential to support the development of new treatments and improve the lives of people with Parkinson's disease.
Researchers developed a novel EIT-EVA PCB sensor for non-invasive assessment of drug inhibition on ion channels. The system enables real-time monitoring of ion flow changes in response to drug exposure, offering a faster and more efficient alternative to traditional methods.
Researchers at Ben-Gurion University of the Negev have developed a new compound, PL-18, which disrupts bacterial quorum sensing and biofilm formation. This compound has shown promise in reducing bacterial virulence and inhibiting iron uptake, suggesting potential applications in combating antibiotic-resistant bacteria.
A rhodium-catalyzed [2+2+1] cycloaddition reaction expands the possibilities for creating complex organic molecules. The researchers achieved high enantiomeric excess values of 94-99% using phosphine ligands, enabling the synthesis of diverse compounds.
Researchers found that rotifers acquire genes from bacteria and produce resistance weapons, such as antibiotics and antimicrobial agents. The team's findings suggest that rotifers could give important clues in the hunt for new antibiotics to treat human infections.
A team of UCSF specialists predicts 24-hour seizure risk using brain activity patterns that foreshadow seizures. The discovery may improve quality of life for 2.9 million Americans living with epilepsy.
Researchers at Hokkaido University have developed a comprehensive derivative synthesis method to find new antimicrobial drugs. They identified eight analogs possessing strong MraY inhibitory and antibacterial activity, with one showing promising effectiveness in mouse infection models.
Researchers at the University of Cambridge have developed an atlas of proteins that reveals how they behave inside human cells. The tool allows for the identification of new proteins involved in important bodily functions, including fat distribution and protein creation.
The University of Texas at Arlington's Junha Jeon is developing transition metal-free cross-coupling technologies using arynes to deliver medications safely and effectively. This project aims to improve the production of drugs, particularly for cancer treatment, by reducing impurities left behind by metals.
A study found that targeting heparan sulfate-modified proteins improves cell repair, rescues neuron loss and reverses cellular changes associated with neurodegenerative diseases. Disrupting these proteins promotes autophagy-dependent cell repair and reverses early cellular problems in models of Alzheimer's.
Researchers at EPFL have created a deep learning pipeline to design soluble analogues of cell membrane proteins, making them easier to study and use in pharmaceutical development. The approach has shown remarkable success in producing functional proteins that maintain parts of their native functionality.
TopoFormer uses a transformer model trained on tens of thousands of protein-drug interactions to recreate 3D structures as one-dimensional information that current models can understand. This enables more accurate predictions of new drug interactions and potentially reduces development time and costs.
Scientists have identified a mechanism that enables enzymes to communicate and produce organic molecules with disease-fighting properties. This breakthrough could aid in the discovery of new drugs by allowing researchers to design or modify enzymes to create novel natural products.
PSICHIC uses sequence data and AI to decode protein-molecule interactions with state-of-the-art accuracy, eliminating costly processes like 3D structures. The tool effectively screens new drug candidates and performs selectivity profiling, offering a more efficient and reliable approach to drug discovery.
Scientists have created mirror-image cyclodextrins in the laboratory, which could make it easier to formulate and deliver complex medications. These discoveries may also lead to improved treatment of cardiovascular diseases caused by atherosclerotic plaques.